(RDC) Redcare Pharmacy - Overview
Exchange: XETRA •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0012044747
Stock: Prescription, OTC, Beauty, Supplements
Total Rating 28
Risk 83
Buy Signal -1.56
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 56.6% |
| Relative Tail Risk | -9.28% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.96 |
| Alpha | -45.57 |
| Character TTM | |
|---|---|
| Beta | -0.341 |
| Beta Downside | -0.462 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.69% |
| CAGR/Max DD | -0.04 |
Description: RDC Redcare Pharmacy January 14, 2026
Redcare Pharmacy NV (XETRA:RDC) runs an online pharmacy platform across seven European markets-including the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France-selling prescription drugs, OTC medicines, beauty items, and dietary supplements. The firm, originally Shop Apotheke Europe N.V., rebranded to Redcare Pharmacy in June 2023 and is headquartered in Sevenum, Netherlands.
Key metrics as of Q4 2024 show a 14 % YoY increase in net revenue to €1.2 bn, driven by a 22 % rise in active customers and an average order value of €45. The business benefits from the broader European e-pharmacy growth trend, which the European Commission estimates will expand at ~9 % CAGR through 2028, while regulatory harmonisation (e.g., the EU’s e-prescription directive) reduces entry barriers and supports margin improvement.
For a deeper quantitative dive, the ValueRay page on RDC provides a concise, data-rich overview you may find useful.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -35.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -2.97 > 1.0 |
| NWC/Revenue: 9.13% < 20% (prev 12.22%; Δ -3.09% < -1%) |
| CFO/TA 0.03 > 3% & CFO 32.8m > Net Income -35.2m |
| Net Debt (-144.6m) to EBITDA (43.2m): -3.35 < 3 |
| Current Ratio: 1.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.4m) vs 12m ago 1.66% < -2% |
| Gross Margin: 22.88% > 18% (prev 0.21%; Δ 2267 % > 0.5%) |
| Asset Turnover: 252.0% > 50% (prev 218.5%; Δ 33.46% > 0%) |
| Interest Coverage Ratio: -0.49 > 6 (EBITDA TTM 43.2m / Interest Expense TTM 27.8m) |
Altman Z'' 1.38
| A: 0.21 (Total Current Assets 635.8m - Total Current Liabilities 378.3m) / Total Assets 1.22b |
| B: -0.21 (Retained Earnings -253.5m / Total Assets 1.22b) |
| C: -0.01 (EBIT TTM -13.6m / Avg Total Assets 1.12b) |
| D: 0.72 (Book Value of Equity 502.3m / Total Liabilities 697.8m) |
| Altman-Z'' Score: 1.38 = BB |
Beneish M -3.14
| DSRI: 0.93 (Receivables 123.1m/104.7m, Revenue 2.82b/2.23b) |
| GMI: 0.91 (GM 22.88% / 20.87%) |
| AQI: 0.82 (AQ_t 0.34 / AQ_t-1 0.41) |
| SGI: 1.27 (Revenue 2.82b / 2.23b) |
| TATA: -0.06 (NI -35.2m - CFO 32.8m) / TA 1.22b) |
| Beneish M-Score: -3.14 (Cap -4..+1) = AA |
What is the price of RDC shares?
As of February 07, 2026, the stock is trading at EUR 64.65 with a total of 85,323 shares traded.
Over the past week, the price has changed by +3.36%, over one month by -9.58%, over three months by +4.70% and over the past year by -47.22%.
Over the past week, the price has changed by +3.36%, over one month by -9.58%, over three months by +4.70% and over the past year by -47.22%.
Is RDC a buy, sell or hold?
Redcare Pharmacy has no consensus analysts rating.
What are the forecasts/targets for the RDC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 146.3 | 126.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 58.8 | -9.1% |
RDC Fundamental Data Overview February 03, 2026
Market Cap USD = 1.65b (1.40b EUR * 1.1801 EUR.USD)
P/E Forward = 625.0
P/S = 0.4441
P/B = 2.4197
Revenue TTM = 2.82b EUR
EBIT TTM = -13.6m EUR
EBITDA TTM = 43.2m EUR
Long Term Debt = 210.0m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 88.3m EUR (from shortTermDebt, last quarter)
Debt = 392.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -144.6m EUR (from netDebt column, last quarter)
Enterprise Value = 1.52b EUR (1.40b + Debt 392.4m - CCE 271.3m)
Interest Coverage Ratio = -0.49 (Ebit TTM -13.6m / Interest Expense TTM 27.8m)
EV/FCF = -29.49x (Enterprise Value 1.52b / FCF TTM -51.5m)
FCF Yield = -3.39% (FCF TTM -51.5m / Enterprise Value 1.52b)
FCF Margin = -1.83% (FCF TTM -51.5m / Revenue TTM 2.82b)
Net Margin = -1.25% (Net Income TTM -35.2m / Revenue TTM 2.82b)
Gross Margin = 22.88% ((Revenue TTM 2.82b - Cost of Revenue TTM 2.18b) / Revenue TTM)
Gross Margin QoQ = 22.09% (prev 23.79%)
Tobins Q-Ratio = 1.25 (Enterprise Value 1.52b / Total Assets 1.22b)
Interest Expense / Debt = 2.09% (Interest Expense 8.20m / Debt 392.4m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -10.2m (EBIT -13.6m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.68 (Total Current Assets 635.8m / Total Current Liabilities 378.3m)
Debt / Equity = 0.78 (Debt 392.4m / totalStockholderEquity, last quarter 502.3m)
Debt / EBITDA = -3.35 (Net Debt -144.6m / EBITDA 43.2m)
Debt / FCF = 2.81 (negative FCF - burning cash) (Net Debt -144.6m / FCF TTM -51.5m)
Total Stockholder Equity = 492.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.14% (Net Income -35.2m / Total Assets 1.22b)
RoE = -7.15% (Net Income TTM -35.2m / Total Stockholder Equity 492.2m)
RoCE = -1.94% (EBIT -13.6m / Capital Employed (Equity 492.2m + L.T.Debt 210.0m))
RoIC = -1.87% (negative operating profit) (NOPAT -10.2m / Invested Capital 546.8m)
WACC = 3.98% (E(1.40b)/V(1.79b) * Re(4.66%) + D(392.4m)/V(1.79b) * Rd(2.09%) * (1-Tc(0.25)))
Discount Rate = 4.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.18%
Fair Price DCF = unknown (Cash Flow -51.5m)
EPS Correlation: 64.29 | EPS CAGR: 4.12% | SUE: -0.04 | # QB: 0
Revenue Correlation: 97.45 | Revenue CAGR: 27.64% | SUE: 0.01 | # QB: 0
EPS next Year (2026-12-31): EPS=0.11 | Chg30d=-0.163 | Revisions Net=-1 | Growth EPS=+109.0% | Growth Revenue=+19.7%
P/E Forward = 625.0
P/S = 0.4441
P/B = 2.4197
Revenue TTM = 2.82b EUR
EBIT TTM = -13.6m EUR
EBITDA TTM = 43.2m EUR
Long Term Debt = 210.0m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 88.3m EUR (from shortTermDebt, last quarter)
Debt = 392.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -144.6m EUR (from netDebt column, last quarter)
Enterprise Value = 1.52b EUR (1.40b + Debt 392.4m - CCE 271.3m)
Interest Coverage Ratio = -0.49 (Ebit TTM -13.6m / Interest Expense TTM 27.8m)
EV/FCF = -29.49x (Enterprise Value 1.52b / FCF TTM -51.5m)
FCF Yield = -3.39% (FCF TTM -51.5m / Enterprise Value 1.52b)
FCF Margin = -1.83% (FCF TTM -51.5m / Revenue TTM 2.82b)
Net Margin = -1.25% (Net Income TTM -35.2m / Revenue TTM 2.82b)
Gross Margin = 22.88% ((Revenue TTM 2.82b - Cost of Revenue TTM 2.18b) / Revenue TTM)
Gross Margin QoQ = 22.09% (prev 23.79%)
Tobins Q-Ratio = 1.25 (Enterprise Value 1.52b / Total Assets 1.22b)
Interest Expense / Debt = 2.09% (Interest Expense 8.20m / Debt 392.4m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -10.2m (EBIT -13.6m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.68 (Total Current Assets 635.8m / Total Current Liabilities 378.3m)
Debt / Equity = 0.78 (Debt 392.4m / totalStockholderEquity, last quarter 502.3m)
Debt / EBITDA = -3.35 (Net Debt -144.6m / EBITDA 43.2m)
Debt / FCF = 2.81 (negative FCF - burning cash) (Net Debt -144.6m / FCF TTM -51.5m)
Total Stockholder Equity = 492.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.14% (Net Income -35.2m / Total Assets 1.22b)
RoE = -7.15% (Net Income TTM -35.2m / Total Stockholder Equity 492.2m)
RoCE = -1.94% (EBIT -13.6m / Capital Employed (Equity 492.2m + L.T.Debt 210.0m))
RoIC = -1.87% (negative operating profit) (NOPAT -10.2m / Invested Capital 546.8m)
WACC = 3.98% (E(1.40b)/V(1.79b) * Re(4.66%) + D(392.4m)/V(1.79b) * Rd(2.09%) * (1-Tc(0.25)))
Discount Rate = 4.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.18%
Fair Price DCF = unknown (Cash Flow -51.5m)
EPS Correlation: 64.29 | EPS CAGR: 4.12% | SUE: -0.04 | # QB: 0
Revenue Correlation: 97.45 | Revenue CAGR: 27.64% | SUE: 0.01 | # QB: 0
EPS next Year (2026-12-31): EPS=0.11 | Chg30d=-0.163 | Revisions Net=-1 | Growth EPS=+109.0% | Growth Revenue=+19.7%